news
Oligomerix names new interim CEO to push Alzheimer's drug
Oligomerix just appointed Dr. Cara Cassino as interim CEO, tapping her 25 years of drug development experience to advance its Alzheimer's pipeline. Cassino has over 25 FDA and EMA drug approvals under her belt from previous roles at major pharma companies like Boehringer Ingelheim, signaling a push for speed to market in the neurodegenerative space.
Oligomerix just appointed Dr. Cara Cassino as interim CEO, tapping her 25 years of drug development experience to advance its Alzheimer's pipeline. Cassino has over 25 FDA and EMA drug approvals under her belt from previous roles at major pharma companies like Boehringer Ingelheim, signaling a push for speed to market in the neurodegenerative space.
The architecture take
A new interim CEO, especially one with a stack of FDA and EMA approvals like Dr. Cassino, tells me Oligomerix is serious about moving its Alzheimer's candidates through clinical trials, fast. This isn't just a leadership change; it's a statement of intent to accelerate drug development. For anyone watching the longevity space, especially those with family history of neurodegeneration, these personnel moves matter because they directly influence how quickly new treatments for brain aging — like tau aggregation inhibitors — actually hit the market. It's a signal to investors and the scientific community that this company means business. I pay attention to who runs these trials because it changes the timeline for what we'll eventually have access to for cognitive health. This kind of hire means they're aiming for a real impact on how our brains age.